References
1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine.2020;382(8):727-733.
2. World Health Organization (WHO). Pneumonia of unknown cause - China. 01/05/2020; https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/. Accessed 04/15/2020.
3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England). 2020;395(10224):565-574.
4. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus–The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020.
5. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020 [press release]. 02/11/2020.
6. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [press release]. 03/11/2020.
7. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious diseases. 2020.
8. World Health Organization (WHO). Coronavirus disease 2019 (COVID-19) Situation Report - 120. 05/19/2020.
9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature.2020;579(7798):270-273.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.
11. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. International forum of allergy & rhinology. 2020.
12. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020.
13. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020:200490.
14. Centers for Disease Control and Prevention (CDC). Interim infection prevention and control guidance for dental settings during the COVID-19 response. 2020; https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html. Accessed 04/15/2020.
15. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England journal of medicine. 2020;382(16):1564-1567.
16. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clinical oral investigations. 2020;24(4):1619-1621.
17. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020.
18. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life sciences.2020;63(3):457-460.
19. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of pathology. 2004;203(2):631-637.
20. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.Frontiers of medicine. 2020.
21. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International journal of oral science. 2020;12(1):8.
22. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2019;25(3):372-378.
23. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.2020.
24. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious diseases. 2020;20(5):565-574.
25. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a non-invasive specimen for detection of SARS-CoV-2. Journal of clinical microbiology. 2020.
26. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv. 2020.
27. U.S. Food & Drug Administration (FDA). Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 assay accelerated emergency use authorization (EUA) summary. https://www.fda.gov/media/136875/download. Accessed 04/14/2020.
28. Harrel SK, Molinari J. Aerosols and splatter in dentistry: a brief review of the literature and infection control implications.Journal of the American Dental Association (1939).2004;135(4):429-437.
29. Bentley CD, Burkhart NW, Crawford JJ. Evaluating spatter and aerosol contamination during dental procedures. Journal of the American Dental Association (1939). 1994;125(5):579-584.
30. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. International journal of oral science. 2020;12(1):9.
31. Occupational Safety and Health Administration (OSHA). Guidance on preparing workplaces for COVID-19. https://www.osha.gov/Publications/OSHA3990.pdf. Accessed 04/15/2020.
32. American Dental Association (ADA). ADA interim guidance for minimizing risk of COVID-19 transmission. https://www.ada.org/~/media/CPS/Files/COVID/ADA_COVID_Int_Guidance_Treat_Pts.pdf?utm_source=adaorg&utm_medium=covid-statement-200401&utm_content=cv-pm-ebd-interim-response&utm_campaign=covid-19. Accessed 04/14/2020.
33. American Association of Oral and Maxillofacial Surgeons (AAOMS). COVID-19 guidance FAQs. https://www.aaoms.org/practice-resources/covid-19-guidance-faqs. Accessed 04/15/2020.
34. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Infectious diseases and therapy. 2018;7(2):249-259.
35. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents.The Japanese journal of veterinary research. 2004;52(3):105-112.
36. Maniakas A, Jozaghi Y, Zafereo ME, et al. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head & neck. 2020.
37. Swennen GRJ, Pottel L, Haers PE. Custom-made 3D-printed face masks in case of pandemic crisis situations with a lack of commercially available FFP2/3 masks. International journal of oral and maxillofacial surgery. 2020.
38. Prusa Research. 3D printed face shields for medics and professionals. 2020; https://www.prusa3d.com/covid19/. Accessed 04/15/2020.
39. American Medical Association (AMA). COVID-19: A physician practice guide to reopening. 5/1/2020; https://www.ama-assn.org/system/files/2020-05/physican-guide-reopening-practices-covid-19.pdf.
40. Centers for Medicare & Medicaid Services (CMS). Re-opening facilities to provide non-emergent non-COVID-19 healthcare: Phase 1. 4/19/2020; https://www.cms.gov/files/document/covid-flexibility-reopen-essential-non-covid-services.pdf.